Skip to main content

Lorena Valero Arrese

Metgessa adjunta del servei d'Oncohematologia Pediàtrica.

Institutions of which they are part

Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca
Doctor
Paediatric Oncology and Haematology
Children's Hospital and Woman's Hospital

Lorena Valero Arrese

Institutions of which they are part

Childhood Cancer and Blood Disorders
Vall Hebron Institut de Recerca
Doctor
Paediatric Oncology and Haematology
Children's Hospital and Woman's Hospital

Metgessa adjunta del servei d'Oncohematologia Pediàtrica.

Després de llicenciar-me en Medicina en la Universitat del País Basc, vaig realitzar la residència en Pediatria a l'Hospital Virgen de las Nieves de Granada, centrant el meu últim any de formació en el camp de l'oncohematologia. Des de 2017 formo part de l'equip d'Oncohematologia Pediàtrica de Vall d'Hebron, i les meves àrees d'especial interès són els assajos clínics en fase precoç i la histiocitosis de cèl·lules de Langerhans.

Projects

Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Miguel Segura Ginard, Lorena Valero Arrese, Raquel Hladun Alvaro, Elena Antima Martinez Saez, Marta Sese Faustino, Gabriela Guillén Burrieza, Josep Roma Castanyer, Andrea Vilaplana Blanes, Estela Carrasco López, Margarita Ortega Blanco, Implementation and new biomarker development for Personalised Medicine for Childhood Cancers in Spain, Asbleidy Carolina Torres Barbosa, Berta Campos Estela
Funding agency: Instituto de Salud Carlos III
Funding: 369260
Reference: PMP21/00073
Duration: 01/01/2022 - 31/12/2025

Next generation personalised medicine for childhood cancers

IP: Lucas Moreno Martín-Retortillo
Collaborators: Aroa Soriano Fernández, Jessica Camacho Soriano, Raquel Hladun Alvaro, Gabriela Guillén Burrieza, Andrea Vilaplana Blanes, Lorena Valero Arrese, Mariona Morell Daniel
Funding agency: Instituto de Salud Carlos III
Funding: 214170
Reference: PI21/01661
Duration: 01/01/2022 - 30/06/2026

Related news

The initiative aims to transform and improve how clinical trials are conducted in the field of rare diseases.

The charitable initiative will allocate all funds to research on pediatric nervous system tumors carried out at the Vall d’Hebron Research Institute

The study, led by Dr. Lucas Moreno and University of Birmingham shows that the combined administration of chemotherapy and immunotherapy with the antibody dinutuximab beta achieves a better treatment response.

Related professionals

Trond Aasen

Trond Aasen

Main researcher
Translational Molecular Pathology
Read more
Anastasia Culea

Anastasia Culea

Research assistant
General Surgery
Read more
Elisa Carenza

Elisa Carenza

Predoctoral researcher
Neurovascular Diseases
Read more
Hector Mauricio Torres Rios

Hector Mauricio Torres Rios

Reconstructive Surgery of the Locomotor System
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.